Skip To Main Content
Uchechukwu Ikeaba on Muck Rack

Uchechukwu Ikeaba

As seen in: JAMA Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Uchechukwu

Contact Uchechukwu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction | Cardiology | JAMA Cardiology | JAMA Network

|
By Mohammad Jawad, Kansas City, John A. Spertus, Uchechukwu Ikeaba
| JAMA Cardiology
Key Points Question How has the adoption rate and variation in use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) changed for US patients with heart failure and left ventricular ejection fraction greater than 40% since publication of clinical trial evidence of benefit in 2021?
Open in Who Shared Issue with article?

Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry | Cardiology | JAMA Cardiology | JAMA Network

|
By Jacob Pierce, Muthiah Vaduganathan, Gregg C. Fonarow, Uchechukwu Ikeaba
| JAMA Cardiology
Key Points Question What is the prevalence and variability of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use among patients with heart failure with reduced ejection fraction (HFrEF) in the US? Findings In this cohort study including 49 399 patients hospitalized for HFrEF in the Get With The Guidelines–Heart Failure registry, 1 in 5 patients were discharged with prescriptions for SGLT2i therapy; rates were similarly low in patients with comorbid type 2 diabetes and chronic kidney disease.
Open in Who Shared Issue with article?
See all 2 articles